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of Bezafibrate as a Potential
TreatmentofMitochondrialDisordersDear Editor,
Genetic defects of mitochondrial respi-
ratory chain (RC) formanexpanding family
of rare diseases, whose number and
global incidence increase constantly,
whereas treatment options remain ex-
tremely limited. In linewith recent literature
data (Bastin et al., 2008) suggesting
a potential of bezafibrate for correction of
RC defects in human fibroblasts, Viscomi
et al. recently published inCellMetabolism
the results of in vivo experiments aimed at
evaluating the effects of bezafibrate inRC-
deficient knockout mice (Viscomi et al.,
2011). The conclusions from this study ap-
peared in marked contrast with those
drawn from in vitro studies in patient cells
and apparently cast doubt on therapeutic
properties of bezafibrate in RC defi-
ciencies. However, we consider that limi-
tations in the study design could explain
the apparent inefficacy and toxic effects
of bezafibrate reported by the authors.
Furthermore, based on clinical data ob-
tained in individuals treated with bezafi-
brate, we present data showing that this
drug can stimulate the RC function in the
human skeletal muscle.
One of the most questionable points in
the study of Viscomi et al. (2011) is the be-
zafibrate dosage tested in the knockout
mice (0.5% drug added to standard diet
for 1 month), for several reasons. At first,
when using this diet, it is easy to calculate
that the daily drug supply is in consider-
able excess compared to the pharmaco-
logical dose used in humans. Indeed,
assuming a mouse body weight of
25–30 g and a 4 g/day food intake, 0.5%
bezafibrate in chow is equivalent to 666–
800 mg/kg/day bezafibrate, i.e., repre-
sents up to 80-fold the dose used for the
treatment of dyslipidemia (10 mg/kg/
day). The second and main concern is
the known toxicity and carcinogenic
potential of such high doses of fibrate in
rodents, established in the early 1980s.
Indeed, it is known that a 2-fold increase
in liver weight is already observed in mice
after 1 week on a diet containing 0.5%
bezafibrate, likely due to PPAR-a-medi-
ated induction of genes involved in hepa-tocyte proliferation (cyclin D1, CDK4,
and c-Myc), whereas mice kept on this
regimen will develop hepatocarcinoma in
the long term (Hays et al., 2005). Impor-
tantly, recent studies also show that clini-
cally relevant doses of bezafibrate elicit
triglyceride-lowering effects in mice, and
no toxic effects (Nakajima et al., 2009).
Taking into account these literaturedata,
there is no rationale to use 0.5% bezafi-
brate in diet when investigating pharmaco-
logical propertiesof thisdrug.Furthermore,
it appears likely that liver hepatomegaly re-
ported both in treated Surf 1/ and wild-
type animals reflects a classical toxic
response to high doses of bezafibrate.
PPAR agonists at high doses can also
induce muscle damages (myofibril degen-
eration and inflammatory cell infiltration).
Accordingly, worsening of muscle
damages in ACTA-Cox15/ mice treated
by bezafibrate could also be ascribed to
toxic effects of bezafibrate overdosage.
Under these conditions, conclusions on
the therapeutic potential of bezafibrate in
RC-deficient mouse models cannot be
drawn, and extrapolation to the treatment
ofRC-deficient patients appears irrelevant.
Importantly, the hepatotoxicity and
carcinogenic activity of fibrates are clearly
rodent specific. Indeed, it has long been
known that humans are resistant to the
development of hepatocarcinoma after
chronic exposure to fibrates, and large-
scale studies performed since the 1980s
consistently established that bezafibrate
is a safe drug, with limited side effects
(Tenenbaum et al., 2005, cited in Bonne-
font et al., 2010).
Regarding the possible use of this drug
in patients with inborn metabolic myopa-
thies, we tested bezafibrate in patients
with the myopathic form of carnitine
palmitoyltransferase 2 (CPT2) deficiency,
one of themost common inbornmitochon-
drial fatty acid b-oxidation defects. In
contrastwith the assumptionmadebyVis-
comi et al. (2011) on thebasis of their study
inmice, this pilot trial did not reveal contra-
indications in the use of bezafibrate in
myopathic patients. On the contrary,
CPT2-deficient patients treated by bezafi-Cell Metabolism 14,brate for 6months at 10mg/kg/day gener-
allyexperiencedacleardecline inmuscular
pain and rhabdomyolysis episodes, and
less limitation in physical activity. Further-
more, follow up of these patients for 3
years indicated stable beneficial effects
of the treatment in the long term, without
adverse effects (Bonnefont et al., 2010).
Importantly, as reported here (see
Figure S1 available online), we established
in the course of this trial that bezafibrate
treatment led to an increase in RCcapacity
in the human skeletal muscle. Indeed,
stimulation of RC capacities was reflected
by the rise in maximal O2 consumption
observed in muscle mitochondria of
treated patients. Thus, as shown in Fig-
ure S1A, the oxidation rates of pyruvate +
malate (a RC complex I substrate) or of
succinate (a RC complex II substrate)
markedly increased (p = 0.028, two-sided
Wilcoxon signed-rank test) after 6 months
of bezafibrate treatment in patient muscle
mitochondria. Consistent with this, the
levels of key RC proteins, i.e., NDUFV1
(complex I) and COX4 (complex IV), en-
coded by nuclear genes, or COX2,
a mitochondrial DNA-encoded gene, were
found strongly increased in the muscle of
bezafibrate-treated patients (Figure S1B).
Finally, cytochrome c oxidase (complex
IV, COX) and citrate synthase (mitochon-
drial matrix protein) enzymeactivitiesmea-
sured inmuscle homogenates significantly
increase after bezafibrate treatment (Fig-
ures S1C and S1D).
Altogether, our in vivo data, as well as
in vitro studies performed in patients’
cells, reinforce the notion that activation
of the PPAR-PGC1 signaling pathway
by bezafibrate could be a promising
approach for pharmacological correction
of partial FAO or RC deficiencies. Clinical
trialswill be needed to assess the possible
beneficial effects of bezafibrate in various
RC disorders and the absence of adverse
effects.SUPPLEMENTAL INFORMATION
Supplemental Information includes one figure
and can be found with this article online at
doi:10.1016/j.cmet.2011.11.003.
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